Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects

American Journal of Clinical Nutrition

Volumn 84, Issue 1, 2006, Pages 252-262

  Castilla, Patricia ^a   Echarri, Rocío ^a   Dávalos, Alberto ^a,b   Cerrato, Francisca ^a   Ortega, Henar ^a   Teruel, José Luis ^a   Lucas, Milagros Fernández ^a   Gómez Coronado, Diego ^a   Ortuño, Joaquín ^a,c   Lasunción, Miguel A ^a,c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE FERMENTACIONES INDUSTRIALES CSIC   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Antioxidants; Cardiovascular disease; Cholesterol; Hemodialysis; Inflammation; Oxidized LDL

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ASCORBIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLYPHENOL; QUERCETIN; URIC ACID; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; FLAVONOID; LIPID; PHENOL DERIVATIVE; PLANT EXTRACT; POLYPHENOLS;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; GRAPE JUICE; HEMODIALYSIS; HUMAN; LIPID OXIDATION; MALE; BEVERAGE; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GRAPE; INTESTINE ABSORPTION; LIPID METABOLISM; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY;

VITIS SP.;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; BEVERAGES; BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; FEMALE; FLAVONOIDS; HUMANS; INTESTINAL ABSORPTION; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHENOLS; PLANT EXTRACTS; QUERCETIN; RENAL DIALYSIS; VITIS;

EID: 33747392153     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.1.252     Document Type: Article

References (66)

1. Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadoa L, Sherrard DJ. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977;26:903-10.
2. Sentí M, Romero R, Pedro-Botet J, Pelegrí A, Nogués X, Rubiés-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992;41:1394-9.
3. Clermont G, Lecour S, Lahet J, et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000;47:618-23.
4. Siems W, Quast S, Carluccio F, et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 2002;58(suppl):S12-9.
5. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38.
6. Drueke TB, Khoa TN, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl 2001;78:S114-9.
7. Takenaka T, Takahashi K, Kobayashi T, Oshima E, Iwasaki S, Suzuki H. Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol 2002;58:33-7.
8. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94.
9. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-60.
10. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-8.
11. Nordin Fredrikson G, Hedblad B, Berglund G, Nilsson J. Plasma oxidized LDL: a predictor for acute myocardial infarction? J Intern Med 2003;253:425-9.
12. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-83.
13. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-8.
14. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523-6.
15. Hollman PC, Arts ICW. Flavonols, flavones and flavonols - nature, occurrence and dietary burden. J Sci Food Agr 2000;80:1081-93.
16. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000;130:2073S-85S.
17. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81(suppl):230S-42S.
18. Lapidot T, Harel S, Granit R, Kanner J. Bioavailability of red wine antocyanins as detected in human urine. J Agric Food Chem 1998;46:4297-302.
19. Donovan JL, Bell JR, Kasim-Karakas S, et al. Catechin is present as metabolites in human plasma after consumption of red wine. J Nutr 1999;129:1662-8.
20. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 1995;61:549-54.
21. Hayek T, Fuhrman B, Vaya J, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997;17:2744-52.
22. Nigdikar SV, Williams NR, Griffin BA, Howard AN. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr 1998;68:258-65.
23. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999;100:1050-5.
24. O'Byrne DJ, Devaraj S, Grundy SM, Jialal I. Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr 2002;76:1367-74.
25. Struck M, Watkins T, Tomeo A, Halley J, Bierenbaum M. Effect of red and white wine on serum lipids, platelet aggregation, oxidation products and antioxidants: a preliminary report. Nutr Res 1994;14:1811-9.
26. Freedman JE, Parker C 3rd, Li L, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 2001;103:2792-8.
27. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995;91:1182-8.
28. Estruch R, Sacanella E, Badía E, et al. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers. Atherosclerosis 2004;175:117-23.
29. Blanco-Colío LM, Valderrama M, Alvarez-Sala LA, et al. Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation 2000;102:1020-6.
30. Zenebe W, Pechanova O, Andriantsitohaina R. Red wine polyphenols induce vasorelaxation by increased nitric oxide bioactivity. Physiol Res 2003;52:425-32.
31. Carluccio MA, Siculella L, Ancora MA, et al. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol 2003;23:622-9.
32. Badía E, Sacanella E, Fernández-Sola J, et al. Decreased tumor necrosis factor-induced adhesion of human monocytes to endothelial cells after moderate alcohol consumption. Am J Clin Nutr 2004;80:225-30.
33. Vinson JA, Teufel K, Wu N. Red wine, dealcoholized red wine, and especially grape juice, inhibit atherosclerosis in a hamster model. Atherosclerosis 2001;156:67-72.
34. Waddington E, Puddey IB, Croft KD. Red wine polyphenolic compounds inhibit atherosclerosis in apolipoprotein E-deficient mice independently of effects on lipid peroxidation. Am J Clin Nutr 2004;79:54-61.
35. Stocker R, O'Halloran RA. Dealcoholized red wine decreases atherosclerosis in apolipoprotein E gene-deficient mice independently of inhibition of lipid peroxidation in the artery wall. Am J Clin Nutr 2004;79:123-30.
36. Miller NJ, Rice-Evans CA. Factors influencing the antioxidant activity determined by the ABTS. + radical cation assay. Free Radic Res 1997;26:195-9.
37. Ortega H, Coperías JL, Castilla P, Gómez-Coronado D, Lasunción MA. Liquid chromatographic method for the simultaneous determination of different lipid-soluble antioxidants in human plasma and low-density lipoproteins. J Chromatogr B Analyt Technol Biomed Life Sci 2004;803:249-55.
38. Speek AJ, Schrijver J, Schreurs WH. Fluorometric determination of total vitamin C in whole blood by high-performance liquid chromatography with pre-column derivatization. J Chromatogr 1984;305:53-60.
39. Erlund I, Alfthan G, Siren H, Ariniemi K, Aro A. Validated method for the quantitation of quercetin from human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl 1999;727:179-89.
40. Ortega H, Castilla P, Gomez-Coronado D, et al. Influence of apolipoprotein E genotype on fat-soluble plasma antioxidants in Spanish children. Am J Clin Nutr 2005;81:624-32.
41. Day AP, Kemp HJ, Bolton C, Hartog M, Stansbie D. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. Ann Nutr Metab 1997;41:353-7.
42. Serafini M, Maiani G, Ferro-Luzzi A. Alcohol-free red wine enhances plasma antioxidant capacity in humans. J Nutr 1998;128:1003-7.
43. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(suppl):33-40.
44. Walter R, Mischak H, Haller H. Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESDR patients. Nephrol Dial Transplant 2002;17(suppl):24-9.
45. Viana M, Barbas C, Bonet B, et al. In vitro effects of a flavonoid-rich extract on LDL oxidation. Atherosclerosis 1996;123:83-91.
46. Kinlay S, Behrendt D, Fang JC, et al. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004;43:629-34.
47. Walzem RL, Watkins S, Frankel EN, Hansen RJ, German JB. Older plasma lipoproteins are more susceptible to oxidation: a linking mechanism for the lipid oxidation theories of atherosclerotic cardiovascular disease. Proc Natl Acad Sci U S A 1995;92:7460-4.
48. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995;41:1135-8.
49. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131-9.
50. Lotite SB, Frei B. The increase in human plasma antioxidant capacity after apple consumption is due to the metabolic effect of fructose on urate, not apple-derived antioxidant flavonoids. Free Radic Biol Med 2004;37:251-8.
51. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
52. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
53. Feng AN, Chen YL, Chen YT, Ding YZ, Lin SJ. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-fed rabbits. Circulation 1999;100:2254-9.
54. Jacobson SH, Thylen P, Lundahl J. Three monocyte-related determinants of atherosclerosis in haemodialysis. Nephrol Dial Transplant 2000;15:1414-9.
55. Papayianni A, Alexopoulos E, Giamalis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002;17:435-41.
56. Kusano KF, Nakamura K, Kusano H, et al. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J 2004;68:671-6.
57. Maron DJ, Lu GP, Cai NS, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med 2003;163:1448-53.
58. Devaraj S, Vega-Lopez S, Kaul N, Schonlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931-4.
59. Auger C, Caporiccio B, Landrault N, et al. Red wine phenolic compounds reduce plasma lipids and apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic golden Syrian hamsters (Mesocricetus auratus). J Nutr 2002;132:1207-13.
60. Del Bas JM, Fernández-Larrea J, Blay M, et al. Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats. FASEB J 2005;19:479-81.
61. Pal S, Ho N, Santos C, et al. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 2003;133:700-6.
62. Bursill C, Roach PD, Bottema CD, Pal S. Green tea upregulates the low-density lipoprotein receptor through the sterol-regulated element binding protein in HepG2 liver cells. J Agric Food Chem 2001;49:5639-45.
63. Raederstorff DG, Schlachter MF, Elste V, Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 2003;14:326-32.
64. Pal S, Naissides M, Mamo J. Polyphenolics and fat absorption. Int J Obes Relat Metab Disord 2004;28:324-6.
65. Waterhouse A. Saponins, a new cholesterol fighter, found in red wine. 226th National Meeting of the American Chemical Society. New York, September 7-11, 2003. Internet: http://whfoods.org/genpage.php?pfriendly=1&tname= foodspice&dbid=40 (accessed 2 May 2005).
66. Hollman PC, van Trijp JM, Buysman MN, et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett 1997;418:152-6.